Based on the key indicators related to Corcept Therapeutics' liquidity, profitability, solvency, and operating efficiency, Corcept Therapeutics Incorporated is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in February. At this time, Corcept Therapeutics' Other Assets are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 750.5 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 83.1 M in 2025. Key indicators impacting Corcept Therapeutics' financial strength include:
Investors should never underestimate Corcept Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Corcept Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Corcept Therapeutics Incorporated.
Net Income
128.16 Million
Corcept
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Capital Expenditures
Total Cash From Financing Activities
Change To Liabilities
End Period Cash Flow
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Stock Based Compensation
Sale Purchase Of Stock
Change To Inventory
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Change Receivables
Net Borrowings
Investments
Change To Operating Activities
Total Assets
Other Current Liab
Total Current Liabilities
Accounts Payable
Cash
Other Current Assets
Total Liab
Common Stock
Property Plant Equipment
Total Stockholder Equity
Other Assets
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Long Term Debt
Short Term Investments
Short Long Term Debt Total
Property Plant And Equipment Net
Net Debt
Retained Earnings
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Non Current Liabilities Total
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Current Deferred Revenue
Short Term Debt
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Inventory
Treasury Stock
Net Receivables
Long Term Debt Total
Short Long Term Debt
Net Invested Capital
Long Term Investments
Net Working Capital
Other Liab
Capital Stock
Non Current Liabilities Other
Capital Lease Obligations
Interest Expense
Selling General Administrative
Research Development
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Tax Expense
Depreciation And Amortization
Income Before Tax
Total Other Income Expense Net
Total Revenue
Gross Profit
Cost Of Revenue
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Tax Provision
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Corcept Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Corcept Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Corcept Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Corcept Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corcept Therapeutics Incorporated. Check Corcept Therapeutics' Beneish M Score to see the likelihood of Corcept Therapeutics' management manipulating its earnings.
Corcept Therapeutics Stock Summary
Corcept Therapeutics competes with Ideaya Biosciences, AnaptysBio, MeiraGTx Holdings, Keros Therapeutics, and Edgewise Therapeutics. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 238 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Corcept Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Corcept Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Corcept Therapeutics's current stock value. Our valuation model uses many indicators to compare Corcept Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Corcept Therapeutics competition to find correlations between indicators driving Corcept Therapeutics's intrinsic value. More Info.
Corcept Therapeutics Incorporated is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Corcept Therapeutics Incorporated is roughly 1.98 . At this time, Corcept Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Corcept Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Corcept Therapeutics Systematic Risk
Corcept Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Corcept Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Corcept Therapeutics correlated with the market. If Beta is less than 0 Corcept Therapeutics generally moves in the opposite direction as compared to the market. If Corcept Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Corcept Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Corcept Therapeutics is generally in the same direction as the market. If Beta > 1 Corcept Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Corcept Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Corcept Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Corcept Therapeutics growth as a starting point in their analysis.
Corcept Therapeutics January 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Corcept Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Corcept Therapeutics Incorporated. We use our internally-developed statistical techniques to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on widely used predictive technical indicators. In general, we focus on analyzing Corcept Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Corcept Therapeutics's daily price indicators and compare them against related drivers.
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.